Kiniksa Pharmaceuticals International (KNSA)
Kiniksa Pharmaceuticals International on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
3.8M
Short interest
settlement 2026-10-15
6.8
Days to cover
+0.4 days vs prior
26.4%
Short share of volume
2026-11-03
1
Fails to deliver
settlement 2026-10-14
Mon 11 Jan
Next earnings
estimated date
-$63.1M
Insider flow, 90 days
0 buys, 48 sells
As of 2026-11-03.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in KNSA is 3,763,527 shares, down 113,242 shares over the last month. Over the last 48 readings it ranged from 1,929,100 shares (31 January 2025) to 4,510,188 shares (15 July 2026). At the reported average volume of 555K shares a day that is 6.8 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/knsa" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 3,763,527 | -0.4% | 555,480 | 6.78 |
| 2026-09-30 | 3,778,657 | -2.5% | 589,057 | 6.41 |
| 2026-09-15 | 3,876,769 | +2.3% | 537,855 | 7.21 |
| 2026-08-31 | 3,788,699 | -11.6% | 436,050 | 8.69 |
| 2026-08-14 | 4,283,628 | -0.8% | 447,952 | 9.56 |
| 2026-07-31 | 4,316,859 | -4.3% | 865,012 | 4.99 |
| 2026-07-15 | 4,510,188 | +8.6% | 658,502 | 6.85 |
| 2026-06-30 | 4,154,751 | +41.0% | 1,442,730 | 2.88 |
| 2026-06-15 | 2,946,654 | -3.1% | 514,615 | 5.73 |
| 2026-05-29 | 3,042,330 | -4.2% | 547,377 | 5.56 |
| 2026-05-15 | 3,175,400 | -10.0% | 572,484 | 5.55 |
| 2026-04-30 | 3,529,376 | -13.8% | 1,103,543 | 3.20 |
| 2026-04-15 | 4,093,547 | +0.1% | 566,823 | 7.22 |
| 2026-03-31 | 4,090,136 | +8.6% | 602,765 | 6.79 |
| 2026-03-13 | 3,767,914 | +11.3% | 739,166 | 5.10 |
| 2026-02-27 | 3,384,065 | +10.7% | 615,334 | 5.50 |
| 2026-02-13 | 3,056,374 | -0.3% | 388,755 | 7.86 |
| 2026-01-30 | 3,064,527 | -8.8% | 727,246 | 4.21 |
| 2026-01-15 | 3,359,576 | -5.9% | 729,189 | 4.61 |
| 2025-12-31 | 3,570,712 | +15.0% | 389,230 | 9.17 |
| 2025-12-15 | 3,103,773 | +10.8% | 383,785 | 8.09 |
| 2025-11-28 | 2,801,537 | -2.9% | 352,744 | 7.94 |
| 2025-11-14 | 2,886,194 | +2.1% | 347,899 | 8.30 |
| 2025-10-31 | 2,827,544 | +10.4% | 652,649 | 4.33 |
| 2025-10-15 | 2,560,121 | +1.7% | 368,777 | 6.94 |
| 2025-09-30 | 2,518,371 | +3.5% | 402,916 | 6.25 |
| 2025-09-15 | 2,433,456 | -10.1% | 472,916 | 5.15 |
| 2025-08-29 | 2,707,472 | +29.4% | 378,535 | 7.15 |
| 2025-08-15 | 2,092,794 | -13.9% | 684,030 | 3.06 |
| 2025-07-31 | 2,429,505 | -4.1% | 696,279 | 3.49 |
| 2025-07-15 | 2,533,519 | +22.6% | 594,478 | 4.26 |
| 2025-06-30 | 2,066,717 | -12.4% | 1,428,132 | 1.45 |
| 2025-06-13 | 2,359,063 | -13.2% | 863,236 | 2.73 |
| 2025-05-30 | 2,718,015 | -17.8% | 497,988 | 5.46 |
| 2025-05-15 | 3,305,668 | -0.6% | 498,386 | 6.63 |
| 2025-04-30 | 3,326,674 | +0.3% | 790,245 | 4.21 |
| 2025-04-15 | 3,316,011 | +6.0% | 686,222 | 4.83 |
| 2025-03-31 | 3,129,716 | +1.9% | 508,298 | 6.16 |
| 2025-03-14 | 3,072,555 | +2.4% | 830,656 | 3.70 |
| 2025-02-28 | 3,000,815 | +1.3% | 532,104 | 5.64 |
| 2025-02-14 | 2,961,419 | +53.5% | 603,334 | 4.91 |
| 2025-01-31 | 1,929,100 | -8.5% | 604,826 | 3.19 |
| 2025-01-15 | 2,109,178 | -37.8% | 510,810 | 4.13 |
| 2024-12-31 | 3,388,499 | +4.0% | 425,113 | 7.97 |
| 2024-12-13 | 3,257,519 | -19.0% | 272,542 | 11.95 |
| 2024-11-29 | 4,019,468 | -2.3% | 241,655 | 16.63 |
| 2024-11-15 | 4,114,568 | -2.4% | 339,635 | 12.11 |
| 2024-10-31 | 4,214,677 | +5.2% | 318,248 | 13.24 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 3 November 2026, the short share of KNSA volume is 26.4%, down 11.8 points over the last five sessions. Over the last 30 readings it ranged from 26.2% (30 September 2026) to 76.3% (8 October 2026). The latest reading sits at the bottom of that range. The latest reading is 22.9 points below the 30-session average of 49.2%, on 557K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-03 | 147K | 557K | 26.4% | 0 |
| 2026-11-02 | 144K | 528K | 27.2% | 398 |
| 2026-10-30 | 207K | 564K | 36.6% | 152 |
| 2026-10-29 | 411K | 655K | 62.7% | 0 |
| 2026-10-28 | 398K | 756K | 52.6% | 3 |
| 2026-10-27 | 419K | 1.1M | 38.2% | 1,164 |
| 2026-10-26 | 239K | 612K | 39.1% | 1,358 |
| 2026-10-23 | 97K | 235K | 41.1% | 1,416 |
| 2026-10-22 | 91K | 161K | 56.5% | 5 |
| 2026-10-21 | 187K | 401K | 46.6% | 696 |
| 2026-10-20 | 335K | 603K | 55.6% | 400 |
| 2026-10-19 | 137K | 226K | 60.5% | 0 |
| 2026-10-16 | 146K | 233K | 62.5% | 416 |
| 2026-10-15 | 405K | 680K | 59.6% | 0 |
| 2026-10-14 | 160K | 239K | 67.1% | 191 |
| 2026-10-13 | 154K | 264K | 58.5% | 2 |
| 2026-10-12 | 90K | 155K | 58.0% | 0 |
| 2026-10-09 | 91K | 192K | 47.5% | 0 |
| 2026-10-08 | 130K | 170K | 76.3% | 0 |
| 2026-10-07 | 101K | 167K | 60.6% | 0 |
| 2026-10-06 | 103K | 164K | 62.9% | 246 |
| 2026-10-05 | 76K | 153K | 49.7% | 0 |
| 2026-10-02 | 82K | 143K | 57.0% | 0 |
| 2026-10-01 | 88K | 322K | 27.4% | 0 |
| 2026-09-30 | 76K | 288K | 26.2% | 0 |
| 2026-09-29 | 50K | 85K | 58.1% | 0 |
| 2026-09-28 | 73K | 197K | 36.8% | 0 |
| 2026-09-25 | 45K | 117K | 38.0% | 0 |
| 2026-09-24 | 68K | 166K | 40.8% | 333 |
| 2026-09-23 | 84K | 180K | 46.8% | 1 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 14 October 2026, the fails-to-deliver balance in KNSA is 1 share, down 1 share over the last settlement date. Over the last 30 readings it ranged from 1 share (20 April 2026) to 19,631 shares (30 July 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-14 | 1 | $78.53 | $79 |
| 2026-09-22 | 2 | $78.13 | $156 |
| 2026-09-17 | 9,617 | $77.62 | $746K |
| 2026-09-09 | 1 | $77.09 | $77 |
| 2026-09-08 | 1 | $77.91 | $78 |
| 2026-09-04 | 1 | $80.47 | $80 |
| 2026-09-03 | 178 | $79.89 | $14K |
| 2026-08-28 | 2,050 | $79.80 | $164K |
| 2026-08-27 | 6 | $78.68 | $472 |
| 2026-08-26 | 6 | $80.20 | $481 |
| 2026-08-25 | 5 | $79.38 | $397 |
| 2026-08-20 | 9 | $80.80 | $727 |
| 2026-08-18 | 89 | $79.18 | $7K |
| 2026-08-11 | 543 | $76.53 | $42K |
| 2026-08-04 | 6 | $73.41 | $440 |
| 2026-07-30 | 19,631 | $80.92 | $1.6M |
| 2026-07-29 | 21 | $79.44 | $2K |
| 2026-07-20 | 14 | $63.95 | $895 |
| 2026-07-17 | 2 | $61.11 | $122 |
| 2026-07-14 | 33 | $60.94 | $2K |
| 2026-07-01 | 31 | $63.95 | $2K |
| 2026-06-29 | 9,678 | $59.20 | $573K |
| 2026-06-18 | 1,252 | $54.21 | $68K |
| 2026-05-19 | 20 | $53.64 | $1K |
| 2026-05-05 | 100 | $57.62 | $6K |
| 2026-04-24 | 1 | $43.05 | $43 |
| 2026-04-20 | 1 | $44.90 | $45 |
| 2026-04-02 | 5,712 | $48.13 | $275K |
| 2026-02-24 | 131 | $47.39 | $6K |
| 2026-01-05 | 1,576 | $42.01 | $66K |
Insider trades
SEC Form 4, newest first. JSONInsiders at KNSA reported 48 open-market sells worth $63.1M in the last 90 days and no open-market buys. Latest filing: Patel Sanj K (CHAIRMAN & CEO) on 2026-11-03.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-11-03 | Patel Sanj K | CHAIRMAN & CEO | Sell | 5K | $94.25 | $432K | 780K |
| 2026-11-03 | Patel Sanj K | CHAIRMAN & CEO | Sell | 146K | $93.53 | $13.6M | 785K |
| 2026-11-03 | Patel Sanj K | CHAIRMAN & CEO | Sell | 69K | $92.70 | $6.4M | 930K |
| 2026-11-03 | Patel Sanj K | CHAIRMAN & CEO | Sell | 1K | $90.77 | $110K | 999K |
| 2026-11-03 | Patel Sanj K | CHAIRMAN & CEO | Exercise or conversion | 41K | $17.92 | $739K | 1.0M |
| 2026-11-03 | Patel Sanj K | CHAIRMAN & CEO | Exercise or conversion | 89K | $8.83 | $787K | 959K |
| 2026-11-02 | Patel Sanj K | CHAIRMAN & CEO | Sell | 100 | $93.97 | $9K | 870K |
| 2026-11-02 | Patel Sanj K | CHAIRMAN & CEO | Sell | 27K | $93.06 | $2.5M | 870K |
| 2026-11-02 | Patel Sanj K | CHAIRMAN & CEO | Sell | 24K | $91.83 | $2.2M | 897K |
| 2026-11-02 | Patel Sanj K | CHAIRMAN & CEO | Sell | 38K | $91.03 | $3.5M | 921K |
| 2026-11-02 | Patel Sanj K | CHAIRMAN & CEO | Exercise or conversion | 53K | $8.83 | $471K | 959K |
| 2026-11-02 | Ragosa Mark | CHIEF FINANCIAL OFFICER | Sell | 220 | $94.01 | $21K | 21K |
| 2026-11-02 | Ragosa Mark | CHIEF FINANCIAL OFFICER | Sell | 12K | $93.13 | $1.1M | 21K |
| 2026-11-02 | Ragosa Mark | CHIEF FINANCIAL OFFICER | Sell | 11K | $92.03 | $966K | 33K |
| 2026-11-02 | Ragosa Mark | CHIEF FINANCIAL OFFICER | Sell | 14K | $91.40 | $1.3M | 44K |
| 2026-11-02 | Ragosa Mark | CHIEF FINANCIAL OFFICER | Exercise or conversion | 10K | $17.76 | $171K | 58K |
| 2026-11-02 | Ragosa Mark | CHIEF FINANCIAL OFFICER | Exercise or conversion | 12K | $11.97 | $145K | 48K |
| 2026-11-02 | Ragosa Mark | CHIEF FINANCIAL OFFICER | Exercise or conversion | 5K | $11.10 | $60K | 36K |
| 2026-11-02 | Ragosa Mark | CHIEF FINANCIAL OFFICER | Exercise or conversion | 10K | $10.76 | $104K | 30K |
| 2026-11-02 | Moat Ross | CHIEF OPERATING OFFICER | Sell | 722 | $94.05 | $68K | 10K |
| 2026-11-02 | Moat Ross | CHIEF OPERATING OFFICER | Sell | 12K | $93.15 | $1.1M | 11K |
| 2026-11-02 | Moat Ross | CHIEF OPERATING OFFICER | Sell | 9K | $92.05 | $822K | 23K |
| 2026-11-02 | Moat Ross | CHIEF OPERATING OFFICER | Sell | 7K | $91.23 | $610K | 32K |
| 2026-11-02 | Moat Ross | CHIEF OPERATING OFFICER | Exercise or conversion | 6K | $22.89 | $143K | 38K |
| 2026-11-02 | Moat Ross | CHIEF OPERATING OFFICER | Exercise or conversion | 12K | $21.77 | $268K | 32K |
| 2026-11-02 | Moat Ross | CHIEF OPERATING OFFICER | Exercise or conversion | 9K | $18.06 | $170K | 20K |
| 2026-11-02 | Paolini John F. | CHIEF MEDICAL OFFICER | Sell | 704 | $94.09 | $66K | 70K |
| 2026-11-02 | Paolini John F. | CHIEF MEDICAL OFFICER | Sell | 17K | $93.42 | $1.6M | 71K |
| 2026-11-02 | Paolini John F. | CHIEF MEDICAL OFFICER | Sell | 899 | $92.37 | $83K | 87K |
| 2026-11-02 | Paolini John F. | CHIEF MEDICAL OFFICER | Exercise or conversion | 12K | $17.92 | $214K | 88K |
| 2026-11-02 | Paolini John F. | CHIEF MEDICAL OFFICER | Exercise or conversion | 6K | $30.93 | $200K | 76K |
| 2026-10-30 | Patel Sanj K | CHAIRMAN & CEO | Sell | 1K | $98.16 | $141K | 906K |
| 2026-10-30 | Patel Sanj K | CHAIRMAN & CEO | Sell | 2K | $97.34 | $225K | 907K |
| 2026-10-30 | Patel Sanj K | CHAIRMAN & CEO | Sell | 4K | $95.97 | $431K | 910K |
| 2026-10-30 | Patel Sanj K | CHAIRMAN & CEO | Sell | 9K | $94.72 | $842K | 915K |
| 2026-10-30 | Patel Sanj K | CHAIRMAN & CEO | Sell | 16K | $93.62 | $1.5M | 924K |
| 2026-10-30 | Patel Sanj K | CHAIRMAN & CEO | Sell | 19K | $92.77 | $1.7M | 939K |
| 2026-10-30 | Patel Sanj K | CHAIRMAN & CEO | Sell | 41K | $92.01 | $3.8M | 958K |
| 2026-10-30 | Patel Sanj K | CHAIRMAN & CEO | Exercise or conversion | 48K | $8.83 | $420K | 999K |
| 2026-10-30 | Megna Michael R | CHIEF ACCOUNTING OFFICER | Sell | 5K | $97.74 | $523K | 13K |
| 2026-10-30 | Megna Michael R | CHIEF ACCOUNTING OFFICER | Sell | 2K | $97.11 | $164K | 18K |
| 2026-10-30 | Megna Michael R | CHIEF ACCOUNTING OFFICER | Sell | 3K | $96.08 | $302K | 20K |
| 2026-10-30 | Megna Michael R | CHIEF ACCOUNTING OFFICER | Sell | 4K | $94.86 | $351K | 23K |
| 2026-10-30 | Megna Michael R | CHIEF ACCOUNTING OFFICER | Sell | 10K | $94.20 | $896K | 27K |
| 2026-10-30 | Megna Michael R | CHIEF ACCOUNTING OFFICER | Sell | 7K | $92.77 | $634K | 36K |
| 2026-10-30 | Megna Michael R | CHIEF ACCOUNTING OFFICER | Sell | 6K | $91.87 | $554K | 43K |
| 2026-10-30 | Megna Michael R | CHIEF ACCOUNTING OFFICER | Exercise or conversion | 4K | $17.76 | $72K | 49K |
| 2026-10-30 | Megna Michael R | CHIEF ACCOUNTING OFFICER | Exercise or conversion | 7K | $11.97 | $86K | 45K |
| 2026-10-30 | Megna Michael R | CHIEF ACCOUNTING OFFICER | Exercise or conversion | 4K | $11.10 | $44K | 38K |
| 2026-10-30 | Megna Michael R | CHIEF ACCOUNTING OFFICER | Exercise or conversion | 5K | $10.76 | $50K | 34K |
| 2026-10-30 | Moat Ross | CHIEF OPERATING OFFICER | Sell | 3K | $97.76 | $252K | 10K |
| 2026-10-30 | Moat Ross | CHIEF OPERATING OFFICER | Sell | 2K | $97.10 | $171K | 13K |
| 2026-10-30 | Moat Ross | CHIEF OPERATING OFFICER | Sell | 4K | $96.03 | $353K | 15K |
| 2026-10-30 | Moat Ross | CHIEF OPERATING OFFICER | Sell | 6K | $94.92 | $596K | 18K |
| 2026-10-30 | Moat Ross | CHIEF OPERATING OFFICER | Sell | 8K | $93.97 | $792K | 25K |
| 2026-10-30 | Moat Ross | CHIEF OPERATING OFFICER | Sell | 15K | $92.81 | $1.4M | 33K |
| 2026-10-30 | Moat Ross | CHIEF OPERATING OFFICER | Sell | 38K | $92.00 | $3.5M | 48K |
| 2026-10-30 | Moat Ross | CHIEF OPERATING OFFICER | Exercise or conversion | 11K | $18.06 | $197K | 86K |
| 2026-10-30 | Moat Ross | CHIEF OPERATING OFFICER | Exercise or conversion | 16K | $17.76 | $286K | 75K |
| 2026-10-30 | Moat Ross | CHIEF OPERATING OFFICER | Exercise or conversion | 2K | $12.97 | $22K | 59K |
| 2026-10-30 | Moat Ross | CHIEF OPERATING OFFICER | Exercise or conversion | 4K | $11.97 | $45K | 57K |
| 2026-10-30 | Moat Ross | CHIEF OPERATING OFFICER | Exercise or conversion | 21K | $11.10 | $234K | 53K |
| 2026-10-30 | Moat Ross | CHIEF OPERATING OFFICER | Exercise or conversion | 16K | $10.76 | $173K | 32K |
| 2026-10-30 | Paolini John F. | CHIEF MEDICAL OFFICER | Sell | 2K | $97.77 | $211K | 70K |
| 2026-10-30 | Paolini John F. | CHIEF MEDICAL OFFICER | Sell | 2K | $97.06 | $187K | 72K |
| 2026-10-30 | Paolini John F. | CHIEF MEDICAL OFFICER | Sell | 4K | $95.97 | $384K | 74K |
| 2026-10-30 | Paolini John F. | CHIEF MEDICAL OFFICER | Sell | 5K | $94.86 | $457K | 78K |
| 2026-10-30 | Paolini John F. | CHIEF MEDICAL OFFICER | Sell | 7K | $93.91 | $642K | 83K |
| 2026-10-30 | Paolini John F. | CHIEF MEDICAL OFFICER | Sell | 16K | $92.85 | $1.5M | 90K |
| 2026-10-30 | Paolini John F. | CHIEF MEDICAL OFFICER | Sell | 42K | $92.02 | $3.8M | 106K |
| 2026-10-30 | Paolini John F. | CHIEF MEDICAL OFFICER | Exercise or conversion | 39K | $17.92 | $700K | 148K |
| 2026-10-30 | Paolini John F. | CHIEF MEDICAL OFFICER | Exercise or conversion | 39K | $30.93 | $1.2M | 108K |
| 2026-09-03 | Megna Michael R | CHIEF ACCOUNTING OFFICER | Sell | 5K | $80.30 | $369K | 29K |
| 2026-09-01 | Megna Michael R | CHIEF ACCOUNTING OFFICER | Tax withholding | 6K | $79.28 | $438K | 34K |
| 2026-09-01 | Megna Michael R | CHIEF ACCOUNTING OFFICER | Exercise or conversion | 3K | price not stated in the filing | not stated | 39K |
| 2026-09-01 | Megna Michael R | CHIEF ACCOUNTING OFFICER | Exercise or conversion | 2K | price not stated in the filing | not stated | 37K |
| 2026-09-01 | Megna Michael R | CHIEF ACCOUNTING OFFICER | Exercise or conversion | 3K | price not stated in the filing | not stated | 34K |
| 2026-09-01 | Megna Michael R | CHIEF ACCOUNTING OFFICER | Exercise or conversion | 4K | price not stated in the filing | not stated | 32K |
| 2026-09-01 | Moat Ross | CHIEF OPERATING OFFICER | Tax withholding | 4K | $79.28 | $318K | 16K |
| 2026-09-01 | Moat Ross | CHIEF OPERATING OFFICER | Exercise or conversion | 2K | price not stated in the filing | not stated | 20K |
| 2026-09-01 | Moat Ross | CHIEF OPERATING OFFICER | Exercise or conversion | 2K | price not stated in the filing | not stated | 18K |
| 2026-09-01 | Moat Ross | CHIEF OPERATING OFFICER | Exercise or conversion | 2K | price not stated in the filing | not stated | 16K |
| 2026-09-01 | Moat Ross | CHIEF OPERATING OFFICER | Exercise or conversion | 2K | price not stated in the filing | not stated | 15K |
| 2026-09-01 | Paolini John F. | CHIEF MEDICAL OFFICER | Tax withholding | 4K | $79.28 | $319K | 70K |
| 2026-09-01 | Paolini John F. | CHIEF MEDICAL OFFICER | Exercise or conversion | 2K | price not stated in the filing | not stated | 74K |
| 2026-09-01 | Paolini John F. | CHIEF MEDICAL OFFICER | Exercise or conversion | 2K | price not stated in the filing | not stated | 71K |
| 2026-09-01 | Paolini John F. | CHIEF MEDICAL OFFICER | Exercise or conversion | 2K | price not stated in the filing | not stated | 70K |
| 2026-09-01 | Paolini John F. | CHIEF MEDICAL OFFICER | Exercise or conversion | 2K | price not stated in the filing | not stated | 68K |
| 2026-09-01 | Patel Sanj K | CHAIRMAN & CEO | Exercise or conversion | 9K | price not stated in the filing | not stated | 107K |
| 2026-09-01 | Patel Sanj K | CHAIRMAN & CEO | Exercise or conversion | 6K | price not stated in the filing | not stated | 99K |
| 2026-09-01 | Patel Sanj K | CHAIRMAN & CEO | Exercise or conversion | 6K | price not stated in the filing | not stated | 93K |
| 2026-09-01 | Patel Sanj K | CHAIRMAN & CEO | Exercise or conversion | 10K | price not stated in the filing | not stated | 86K |
| 2026-09-01 | Patel Sanj K | CHAIRMAN & CEO | Tax withholding | 15K | $79.28 | $1.2M | 92K |
| 2026-09-01 | Patel Sanj K | CHAIRMAN & CEO | Exercise or conversion | 9K | price not stated in the filing | not stated | 107K |
| 2026-09-01 | Patel Sanj K | CHAIRMAN & CEO | Exercise or conversion | 6K | price not stated in the filing | not stated | 99K |
| 2026-09-01 | Patel Sanj K | CHAIRMAN & CEO | Exercise or conversion | 6K | price not stated in the filing | not stated | 93K |
| 2026-09-01 | Patel Sanj K | CHAIRMAN & CEO | Exercise or conversion | 10K | price not stated in the filing | not stated | 86K |
| 2026-09-01 | Ragosa Mark | CHIEF FINANCIAL OFFICER | Tax withholding | 4K | $79.28 | $349K | 21K |
| 2026-09-01 | Ragosa Mark | CHIEF FINANCIAL OFFICER | Exercise or conversion | 3K | price not stated in the filing | not stated | 25K |
| 2026-09-01 | Ragosa Mark | CHIEF FINANCIAL OFFICER | Exercise or conversion | 2K | price not stated in the filing | not stated | 22K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON29 Form 144 notices on file for KNSA worth $148.5M at the prices reported; 6 in the last 90 days worth $78.6M. Latest: Ragosa Mark filed on 2026-11-02 to sell 36,783 shares ($3.4M) from 2026-11-02.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-11-02 | Ragosa MarkOfficer | 37K | $3.4M | 0.075% | 2026-11-02 | Charles Schwab & Co., Inc. |
| 2026-10-30 | Paolini John F.Officer | 96K | $8.9M | 0.197% | 2026-10-30 | Charles Schwab & Co., Inc. |
| 2026-10-30 | Megna Michael ROfficer | 48K | $4.6M | 0.097% | 2026-10-30 | Charles Schwab & Co., Inc. |
| 2026-10-30 | Moat RossOfficer | 104K | $9.8M | 0.212% | 2026-10-30 | Charles Schwab & Co., Inc. |
| 2026-10-30 | Patel Sanj KOfficer, Director | 554K | $51.6M | 1.134% | 2026-10-30 | Charles Schwab & Co., Inc. |
| 2026-09-03 | Megna Michael ROfficer | 5K | $369K | 0.010% | 2026-09-03 | Charles Schwab & Co., Inc. |
| 2026-07-29 | Tessari EbenFormer Affiliate | 67K | $5.3M | 0.139% | 2026-07-29 | Charles Schwab & Co., Inc. |
| 2026-07-29 | Cole G BradleyDirector | 4K | $299K | 0.008% | 2026-07-29 | Charles Schwab & Co., Inc. |
| 2026-05-01 | Paolini John F.Officer | 58K | $3.1M | 0.126% | 2026-05-01 | Charles Schwab & Co., Inc. |
| 2026-04-28 | Patel Sanj KOfficer, Director | 345K | $17.8M | 0.751% | 2026-04-28 | Charles Schwab & Co., Inc. |
| 2026-04-09 | Moat RossOfficer | 2K | $80K | 0.004% | 2026-04-09 | Charles Schwab & Co., Inc. |
| 2026-04-09 | Megna Michael ROfficer | 7K | $309K | 0.014% | 2026-04-09 | Charles Schwab & Co., Inc. |
| 2026-04-06 | Quart Barry DDirector | 20K | $1.0M | 0.044% | 2026-04-06 | Charles Schwab & Co., Inc. |
| 2026-04-06 | Patel Sanj KOfficer, Director | 220K | $11.0M | 0.478% | 2026-04-06 | Charles Schwab & Co., Inc. |
| 2026-04-06 | Moat RossOfficer | 2K | $115K | 0.005% | 2026-04-06 | Charles Schwab & Co., Inc. |
| 2026-03-09 | Ragosa MarkOfficer | 37K | $1.7M | 0.080% | 2026-03-09 | Charles Schwab & Co., Inc. |
| 2026-03-02 | Paolini John F.Officer | 40K | $1.8M | 0.087% | 2026-03-02 | Charles Schwab & Co., Inc. |
| 2025-12-15 | Quart Barry DDirector | 59K | $2.4M | 0.130% | 2025-12-15 | Charles Schwab & Co., Inc. |
| 2025-12-08 | Ragosa MarkOfficer | 73K | $3.0M | 0.161% | 2025-12-08 | Charles Schwab & Co., Inc. |
| 2025-11-26 | Tessari EbenOfficer | 48K | $2.1M | 0.107% | 2025-11-26 | Charles Schwab & Co., Inc. |
| 2025-11-17 | Tessari EbenOfficer | 12K | $514K | 0.028% | 2025-11-17 | Charles Schwab & Co., Inc. |
| 2025-10-31 | Paolini John F.Officer | 83K | $3.1M | 0.183% | 2025-10-31 | Charles Schwab & Co., Inc. |
| 2025-10-28 | Ragosa MarkOfficer | 20K | $820K | 0.046% | 2025-10-28 | Charles Schwab & Co., Inc. |
| 2025-10-28 | Ragosa MarkOfficer | 20K | $820K | 0.046% | 2025-10-28 | Charles Schwab & Co., Inc. |
| 2025-10-20 | Patel Sanj KOfficer, Director | 258K | $10.0M | 0.593% | 2025-10-20 | Charles Schwab & Co., Inc. |
| 2025-10-20 | Megna Michael ROfficer | 50K | $2.0M | 0.116% | 2025-10-20 | Charles Schwab & Co., Inc. |
| 2025-10-14 | Tessari EbenOfficer | 12K | $466K | 0.028% | 2025-10-14 | Charles Schwab & Co., Inc. |
| 2025-09-29 | Tessari EbenOfficer | 42K | $1.6M | 0.097% | 2025-09-29 | Charles Schwab & Co., Inc. |
| 2025-09-15 | Tessari EbenOfficer | 16K | $598K | 0.038% | 2025-09-15 | Charles Schwab & Co., Inc. |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON9 holders report 5% or more of KNSA in their latest filing, 4 on Schedule 13D (active intent). The largest reported stake is FMR LLC at 14.8% of the class (6,787,700 shares), filed 2026-05-06 for an event on 2026-03-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-07-29 | 13G | BlackRock, Inc.parent holding company | 2.5M | 5.5% | 2026-06-30 |
| 2026-05-26 | 13D/Ano. 6 | Felix J. Bakerindividual, parent holding company | 3.3M | 7.0% | 2026-05-21 |
| 2026-05-26 | 13D/Ano. 6 | Julian C. Bakerindividual, parent holding company | 3.3M | 7.0% | 2026-05-21 |
| 2026-05-26 | 13D/Ano. 6 | Baker Bros. Advisors (GP) LLCparent holding company, other entity | 3.2M | 6.9% | 2026-05-21 |
| 2026-05-26 | 13D/Ano. 6 | Baker Bros. Advisors LPinvestment adviser, partnership | 3.2M | 6.9% | 2026-05-21 |
| 2026-05-26 | 13D/Ano. 6 | FBB3 LLCother entity | 7K | 0.0% | 2026-05-21 |
| 2026-05-06 | 13G/Ano. 1 | FMR LLCparent holding company | 6.8M | 14.8% | 2026-03-31 |
| 2026-05-06 | 13G/Ano. 1 | Abigail P. Johnsonindividual | 6.8M | 14.8% | 2026-03-31 |
| 2026-03-27 | 13G/Ano. 7 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-02-13 | 13G/Ano. 4 | Rubric Capital Management LPinvestment adviser, partnership | 3.3M | 7.4% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 4 | David Rosenparent holding company, individual | 3.3M | 7.4% | 2025-12-31 |
13F holders
Tracked managers holding KNSA at their latest 13F. JSON8 of the 30 tracked managers held KNSA at their latest 13F, $177.0M in total at quarter-end prices. Point72 Asset Management is the largest at $42.2M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 5 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Point72 Asset Management | 2026-06-30 | 659K | $42.2M | 0.05% | +19K |
| D. E. Shaw & Co. | 2026-06-30 | 570K | $36.4M | 0.02% | -390K |
| Two Sigma Investments | 2026-06-30 | 561K | $35.9M | 0.03% | +141K |
| Fisher Asset Management | 2026-06-30 | 398K | $25.5M | 0.01% | -31K |
| AQR Capital Management | 2026-06-30 | 375K | $24.0M | 0.01% | -4K |
| Millennium Management | 2026-06-30 | 93K | $6.0M | 0.00% | -471K |
| Renaissance Technologies | 2026-06-30 | 68K | $4.4M | 0.01% | new |
| Citadel Advisors | 2026-06-30 | 42K | $2.7M | 0.00% | -433K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q3 FY 2026 (quarter ended 2026-09-30) Kiniksa Pharmaceuticals International reported revenue of $286.0M, up 58.1% from the same quarter a year earlier, and net income of $47.3M (0.56 diluted EPS). In FY 2025 it generated $138.0M of operating cash flow.
- Cash
- $81.7M
- Equity
- $710.2M
- Total assets
- $983.2M
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q3 FY 2026 | 2026-09-30 | $286.0M | $47.3M | 16.6% | 0.56 |
| Q2 FY 2026 | 2026-06-30 | $243.6M | $25.4M | 10.4% | 0.30 |
| Q1 FY 2026 | 2026-03-31 | $214.3M | $22.6M | 10.5% | 0.27 |
| Q4 FY 2025derived | 2025-12-31 | $202.1M | $14.2M | 7.0% | n/a |
| Q3 FY 2025 | 2025-09-30 | $180.9M | $18.4M | 10.2% | 0.23 |
| Q2 FY 2025 | 2025-06-30 | $156.8M | $17.8M | 11.4% | 0.23 |
| Q1 FY 2025 | 2025-03-31 | $137.8M | $8.5M | 6.2% | 0.11 |
| Q4 FY 2024derived | 2024-12-31 | $122.5M | -$8.9M | -7.3% | n/a |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $677.6M | $59.0M | $138.0M | $1.6M | n/a | n/a |
| FY 2024 | 2024-12-31 | $423.2M | -$43.2M | $25.7M | $277K | n/a | n/a |
| FY 2023 | 2023-12-31 | $270.3M | $14.1M | $13.3M | $130K | n/a | n/a |
| FY 2022 | 2022-12-31 | $220.2M | $183.4M | $5.8M | $105K | n/a | n/a |
| FY 2021 | 2021-12-31 | $38.5M | -$157.9M | -$126.3M | $415K | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-09-30.
What this page is
Kiniksa Pharmaceuticals International in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Kiniksa Pharmaceuticals International (KNSA), SEC CIK 1730430, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-03.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-14.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-11-02.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-07-29.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-09-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-10-27.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-11-03.JSON and CSV
- Company record
- EDGAR filing index for CIK 1730430Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
Datasets
Frequently Asked Questions
How much of KNSA is sold short?
3,763,527 shares were held short at the 2026-10-15 settlement, 6.8 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is KNSA's daily short volume?
On 2026-11-03, 146,745 of the 556,597 KNSA shares reported to FINRA were sold short, 26.4% of the day's reported volume. Short volume is a flow for one day, not a position.
Does KNSA have fails to deliver?
The SEC's latest file shows 1 KNSA shares failed to deliver at settlement 2026-10-14. Fails are reported per settlement date and published twice a month with a lag.
Are KNSA insiders buying or selling?
Insiders at KNSA reported 48 open-market sells worth $63.1M in the last 90 days and no open-market buys. Latest filing: Patel Sanj K (CHAIRMAN & CEO) on 2026-11-03.
Have KNSA insiders filed to sell?
29 Form 144 notices on file for KNSA worth $148.5M at the prices reported; 6 in the last 90 days worth $78.6M. Latest: Ragosa Mark filed on 2026-11-02 to sell 36,783 shares ($3.4M) from 2026-11-02.
Who owns 5% or more of KNSA?
9 holders report 5% or more of KNSA in their latest filing, 4 on Schedule 13D (active intent). The largest reported stake is FMR LLC at 14.8% of the class (6,787,700 shares), filed 2026-05-06 for an event on 2026-03-31.
What did KNSA report last quarter?
In Q3 FY 2026 (quarter ended 2026-09-30) Kiniksa Pharmaceuticals International reported revenue of $286.0M, up 58.1% from the same quarter a year earlier, and net income of $47.3M (0.56 diluted EPS). In FY 2025 it generated $138.0M of operating cash flow.
Which tracked 13F managers own KNSA?
8 of the 30 tracked 13F managers held KNSA shares at their latest filing, $177.0M in all. The largest: Steve Cohen's Point72 Asset Management (659K shares, $42.2M), D. E. Shaw & Co. (570K shares, $36.4M), Two Sigma Investments (561K shares, $35.9M), Ken Fisher's Fisher Asset Management (398K shares, $25.5M), Cliff Asness's AQR Capital Management (375K shares, $24.0M), Izzy Englander's Millennium Management (93K shares, $6.0M). The table above lists all 8.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.